Shimizu N, Hamaide A, Dourcy M, Noël S, Clercx C, Teske E
Department of Clinical Sciences, FARAH, Faculty of Veterinary Medicine, University of Liège, Liège, Belgium.
Department of Infectious and Parasitic Diseases, FARAH, Faculty of Veterinary Medicine, University of Liège, Liège, Belgium.
Vet Comp Oncol. 2019 Mar;17(1):11-20. doi: 10.1111/vco.12436. Epub 2018 Dec 26.
Chemokine (C-C motif) ligand 2 (CCL2) is a chemotactic cytokine recruiting monocytes, releasing growth factors and promoting adhesion in vascular endothelium. Elevated serum and urinary CCL2 levels and expression of its receptor (CCR2) have been associated with tumorigenesis in human urinary malignancies. CCL2 implication has not been investigated in canine urothelial carcinoma. The aim of this study was to evaluate CCL2 serum and urine levels (measured by ELISA) in dogs with urothelial carcinoma or non-neoplastic urinary tract disease. CCL2 serum and urine levels were significantly higher in diseased dogs compared with healthy dogs (P < 0.001). Dogs with carcinoma had significantly higher serum and urine CCL2 levels (P = 0.001) than healthy dogs. Dogs with metastases showed significantly lower serum and urine CCL2 levels compared with the non-metastasised tumour group (P = 0.007). CCL2 as a diagnostic marker for urothelial carcinoma held a sensitivity of 95.2% and a specificity of 38.2% in the urine. As a staging marker, sensitivity was 85.7% and specificity was 57.1% with a positive predictive value of 75.7% and a negative predictive value of 71.9%. Further investigation is needed to define the role of CCL2 as a prognostic marker in canine urothelial carcinoma.
趋化因子（C-C基序）配体2（CCL2）是一种趋化细胞因子，可募集单核细胞、释放生长因子并促进血管内皮中的黏附。血清和尿液中CCL2水平升高及其受体（CCR2）的表达与人类泌尿系统恶性肿瘤的发生有关。尚未对犬尿路上皮癌中CCL2的作用进行研究。本研究的目的是评估患有尿路上皮癌或非肿瘤性泌尿系统疾病的犬的血清和尿液中CCL2水平（通过ELISA测量）。与健康犬相比，患病犬的血清和尿液中CCL2水平显著更高（P < 0.001）。患有癌症的犬的血清和尿液中CCL2水平显著高于健康犬（P = 0.001）。与未发生转移的肿瘤组相比，发生转移的犬的血清和尿液中CCL2水平显著更低（P = 0.007）。CCL2作为尿路上皮癌的诊断标志物，在尿液中的敏感性为95.2%，特异性为38.2%。作为分期标志物，敏感性为85.7%，特异性为57.1%，阳性预测值为75.7%，阴性预测值为71.9%。需要进一步研究以确定CCL2作为犬尿路上皮癌预后标志物的作用。
